Skip to main content
. 2012 Sep 27;97(12):4287–4292. doi: 10.1210/jc.2012-3080

Fig. 3.

Fig. 3.

Structures of TSHR SMLs. TSHR agonist: NCGC00161870, N-(4-(5-(3-benzyl-5-hydroxy-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)-2-methoxybenzyloxy)-phenyl)acetamide. TSHR neutral antagonist: NCGC00242595, 2-(3-((2,6-dimethylphenylthio)methyl)-4-methoxyphenyl)-3-(furan-2-ylmethyl)-2,3-dihydroquinazolin-4(1H)-one. TSHR inverse agonists: NCGC00161856, 2-(3-((2,6-dimethylphenoxy)methyl)-4-methoxyphenyl)-3-(furan-2-ylmethyl)-2,3-dihydroquinazolin-4(1H)-one]; NCGC00229600, 2-(3-((2,6-dimethylphenoxy)methyl)-4-methoxyphenyl)-3-(pyridin-3-ylmethyl)-2,3-dihydroquinazolin-4(1H)-one; and Org 274179-0, (S)-N-(1-acetyl-4-methyl-4-phenyl-1,2,3,4-tetrahydro-quinolin-6-yl)-3-(3-trifluoromethyl-phenyl)-propionamide.